NTLA is trading 4.2% up at $16.16, following fresh analyst coverage and renewed focus on its positive clinical trial data and regulatory advancements. - Today's news highlights impressive Phase 3 lonvo-z data and the initiation of a rolling Biologics License Application (BLA) submission to the FDA. - Analysts project further significant upside for the stock, building on earlier 2026 FDA and clinical developments for nex-z.